Ideaya Biosciences ( ($IDYA) ) has released its Q4 earnings. Here is a breakdown of the information Ideaya Biosciences presented to its investors.

IDEAYA Biosciences, Inc. (IDYA) has been beaten down lately with too much selling pressure. While the stock has lost 8.6% ...

Wedbush analyst Robert Driscoll maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report) today and set a price target of $52.00.

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into an additional clinical ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

IDEAYA Biosciences named Joshua Bleharski as its top finance chief, effective in early May.

Aligner Experts is proud to announce the opening of three new locations in Chicago, IL, providing increased accessibility to their premium orthodontic services. Their state-of-the-art clinics are ...

America's first state-licensed nurse practitioner (NP), Marie Osborn ARNP, stood in the Idaho Capitol Rotunda on February 11 to release her memoir Moving Mountains, celebrate the NP profession, and ...